Adjuvant therapy for hepatocellular carcinoma after curative treatment

Wen Juei Jeng, Chen Chun Lin, Wei Ting Chen, I. Shyan Sheen, Chun Yen Lin, Shi Ming Lin*

*此作品的通信作者

研究成果: 期刊稿件文章同行評審

17 引文 斯高帕斯(Scopus)

摘要

Hepatocellular carcinoma (HCC) is a common malignancy in the world. Although resection and various locoregional therapies can achieve eradication or complete ablation of small HCC, HCC recurrence after these therapies is still common. Although candidates for medical ablation usually exhibit compensated hepatic functional status, the frequent recurrence of HCC after successful ablation contributes to short survival. Therefore, attempts to prevent HCC recurrence are essential to prolong survival. Efforts in preventing HCC recurrence after curative therapies include prevention of early recurrence by improving liver immunity and eliminating microscopic tumor foci or micrometastases, and prevention of late recurrence by reducing the hepatitis activity and using antiviral therapies based on viral suppression/eradication. In HCC with vascular invasion, adjuvant transcatheter arterial chemoembolization should be considered to provide better control. Whether the adjuvant use of sorafenib may suppress microscopic tumor foci or micrometastases may be unveiled in the near future. This review article will update the algorithms, novel medication or study drugs in the prevention of HCC after curative therapies.

原文英語
頁(從 - 到)747-754
頁數8
期刊Digestive Diseases
32
發行號6
DOIs
出版狀態已出版 - 19 11 2014

文獻附註

Publisher Copyright:
© 2014 S. Karger AG, Basel.

指紋

深入研究「Adjuvant therapy for hepatocellular carcinoma after curative treatment」主題。共同形成了獨特的指紋。

引用此